Radiotherapy and Immunotherapy Combinations for Lung Cancer.
Vishesh AgrawalKimberly Thomas BenjaminEric C KoPublished in: Current oncology reports (2020)
The role of immunotherapy for NSCLC has expanded significantly following the pivotal approvals of nivolumab and pembrolizumab for metastatic NSCLC, maintenance durvalumab in unresectable stage III NSCLC, and atezolizumab for metastatic NSCLC. Several small early-phase trials have demonstrated the ability of RT to elicit clinically significant tumor immunity. These positive findings support current trial efforts combining RT with immunotherapy for NSCLC. Recently initiated trials of RT and immunotherapy hold significant promise in expanding the therapeutic options for NSCLC. Optimization of therapy will require careful patient selection to yield meaningful improvements in clinical outcomes.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- brain metastases
- squamous cell carcinoma
- epidermal growth factor receptor
- clinical trial
- early stage
- radiation therapy
- locally advanced
- randomized controlled trial
- study protocol
- radiation induced
- stem cells
- case report
- big data
- bone marrow
- mesenchymal stem cells
- rectal cancer
- phase ii